We have shown that a CLSPN mutation associated with breast cancer (c.1574A>G; p.Asn525Ser) resulted in either Claspin degradation or decreased Chk1 phosphorylation and, as such, in deficient checkpoint activation [81]. This evidence concerns the gene CLSPN and breast carcinoma.